Medicare Can Cover Anti-Obesity Drugs for Heart Disease -- But at What Cost?
(MedPage Today) -- On March 8, 2024, FDA approved Wegovy (semaglutide) to treat cardiovascular disease risks -- heart attack, stroke, and death -- for obese or overweight adults with a history of cardiovascular disease, making it the first... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 8, 2024 Category: Primary Care Source Type: news
Beta-Blockers Fail to Deliver Secondary Prevention Benefit in Key MI Patients
(MedPage Today) -- ATLANTA -- Beta-blockers had no additive benefit over contemporary therapies for people with acute myocardial infarction (MI) maintaining a preserved left ventricular ejection fraction (LVEF), the REDUCE-AMI randomized trial... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Antisense Drug Slashes High Triglycerides
(MedPage Today) -- ATLANTA -- A novel antisense mRNA drug slashed triglycerides in higher risk or moderate hypertriglyceridemia patients and in those with extremely elevated levels from familial chylomicronemia syndrome, two randomized phase... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Self-Expanding Evolut Valves Edge Out Sapien in Majority-Female TAVR Trial
(MedPage Today) -- ATLANTA -- For transcatheter aortic valve replacement (TAVR) candidates with a small aortic annulus, the two leading platforms offered differing hemodynamic valve performances despite being similarly effective at 1 year, according... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 8, 2024 Category: Cardiology Source Type: news
Wegovy Helps HFpEF Patients With Diabetes Mellitus
(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
Roche and Alnylam present positive results from the Phase II KARDIA-2 study of zilebesiran added to standard of care antihypertensives in patients with inadequately controlled hypertension
The KARDIA-2 study met its primary endpoint demonstrating additive, placebo-adjusted systolic blood pressure reductions of up to 12.1 mmHgat month three. These results were statistically significant and clinically meaningfulZilebesiran demonstrated an encouraging safety and tolerability profile when added to standard of care antihypertensives Basel, 7 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam today released detailed results from the Phase II KARDIA-2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care (SOC) antihypertensives. T...
Source: Roche Investor Update - April 7, 2024 Category: Pharmaceuticals Source Type: news
Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor
(MedPage Today) -- ATLANTA -- The SGLT2 inhibitor empagliflozin (Jardiance) did not exactly prevent deaths and heart failure (HF) events when initiated atop other standard therapies for acute myocardial infarction (MI), the EMPACT-HF trial found... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
Interatrial Shunt's Prospects in Heart Failure Shrink After RELIEVE-HF
(MedPage Today) -- ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's left ventricular ejection... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 7, 2024 Category: Cardiology Source Type: news
New REDUCE-IT ® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) --…#baselinehigh #ldlclevels #dublin #ireland #bridgewater #vascepa #lipoproteina #jacc #nabilabadir #mb (Source: Reuters: Health)
Source: Reuters: Health - April 6, 2024 Category: Consumer Health News Source Type: news
Short-term incentives for exercise can lead to sustained increases in activity
NIH-supported study shows certain perks can spur long-term behavior change in adults with cardiovascular disease risks (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - April 5, 2024 Category: American Health Source Type: news
Specialty Care Access Not Equal Among Teens With Diabetes
(MedPage Today) -- Commercially insured youths with type 2 diabetes were less likely to see specialists compared with their counterparts with type 1 diabetes, a cross-sectional study of claims data indicated.
In propensity score-weighted analyses... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 5, 2024 Category: Cardiology Source Type: news
Cardio Diagnostics Holdings partners with Navierre for cardiac testing
The partnership will expand cardiovascular care to areas without specialized infrastructure like CT imaging. (Source: mobihealthnews)
Source: mobihealthnews - April 5, 2024 Category: Information Technology Source Type: news
Nonhospitalized Patients With Post-COVID Condition Tolerate Exercise
FRIDAY, April 5, 2024 -- Nonhospitalized patients with post-COVID condition (PCC) tolerate exercise, with preserved cardiovascular function, but have lower aerobic capacity, according to a study published online April 4 in JAMA Network Open.
Andrea... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 5, 2024 Category: Pharmaceuticals Source Type: news
Why Heart Disease Research Still Favors Men
Published in partnership with The Fuller Project, a nonprofit newsroom dedicated to the coverage of women’s issues around the world.
Katherine Fitzgerald had just arrived at the party. Before she could even get a drink, she threw up and broke out in a sweat. “I was dizzy. I couldn’t breathe. I had heart pain,” Fitzgerald says.
She knew she was having a heart attack.
[time-brightcove not-tgx=”true”]
What she didn’t know then was that the heart attack could have been prevented. Fitzgerald, a health-conscious, exercise-loving lawyer, should have been taking statin drugs to s...
Source: TIME: Health - April 5, 2024 Category: Consumer Health News Authors: Maggie Fox Tags: Uncategorized freelance healthscienceclimate Source Type: news
MRI shows preeclampsia's effect on maternal heart, fetal brain
MRI reveals the negative effects of preeclampsia on pregnant women's hearts and on the brains of their fetuses, according to research published in the April issue of Hypertension.
The results highlight MRI's benefits as a prenatal assessment tool, wrote a group led by Megan Hall, MD, of St Thomas' Hospital in London, U.K.
"As well as giving insight into the immediate pathophysiological impact of preeclampsia, [MRI] holds potential as a valuable tool for risk stratification both antenatally and when considering longer-term cardiovascular risk in women," it noted.
Preeclampsia is a disease of pregnancy that has both short...
Source: AuntMinnie.com Headlines - April 5, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Clinical News Womens Imaging Ob/Gyn Source Type: news
